The investment is 4 billion Yen and expands Sumitomo’s share in the company to 19,55 %. Bonac is a specialist for modified RNA synthesis (Bonac nucleic acids) which exhibit good stability and may lead to novel mucleic acid drugs.
Bonac news release, September 26, 2017
Sumitomo Chemical invests in nucleic acid drug company Bonac